Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr 30;13(4):647-649.
doi: 10.21037/tau-23-569. Epub 2024 Apr 18.

Ablative therapy with UGN-102 for low-grade intermediate risk non-muscle-invasive bladder cancer: ready for primetime?

Benjamin Lichtbroun  1 , Saum Ghodoussipour  1 , Vignesh T Packiam  1
Affiliations
Editorial

Ablative therapy with UGN-102 for low-grade intermediate risk non-muscle-invasive bladder cancer: ready for primetime?

Benjamin Lichtbroun et al. Transl Androl Urol. .
No abstract available

Keywords: Non-muscle-invasive bladder cancer (NMIBC); ablative therapy; mitomycin.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-569/coif). V.T.P. received consulting fees from Valar Labs. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol 2016;196:1021-9. 10.1016/j.juro.2016.06.049 - DOI - PubMed
    1. Gregg JR, McCormick B, Wang L, et al. Short term complications from transurethral resection of bladder tumor. Can J Urol 2016;23:8198-203. - PubMed
    1. Lindgren MS, Hansen E, Azawi N, et al. DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol 2023;41:206-11. 10.1200/JCO.22.00470 - DOI - PubMed
    1. Matin SF, Pierorazio PM, Kleinmann N, et al. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol 2022;207:779-88. 10.1097/JU.0000000000002350 - DOI - PubMed
    1. Prasad SM, Huang WC, Shore ND, et al. Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS). J Urol 2023;210:619-29. 10.1097/JU.0000000000003645 - DOI - PubMed

LinkOut - more resources